CLAIMS

What is claimed is:

1. A compound of formula



V

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof,

wherein:

R^a, R^b, and R^c are independently hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein the aryl, heteroaryl, arylalkyl, or heteroarylalkyl is optionally substituted with one, two, or three groups independently selected from the group consisting of alkyl, O-alkyl, S-alkyl, OH, SH, -CN, halogen, 1,3-dioxolanyl, CF_3, NO_2, NH_2, $NHCH_3$, $N(CH_3)_2$, NHCO-alkyl, $-(CH_2)_mCO_2H$, $-(CH_2)_mCO_2$-alkyl, $-(CH_2)_mSO_3H$, -NH alkyl, $-N(alkyl)_2$, $-(CH_2)_mPO_3H_2$, $-(CH_2)_mPO_3(alkyl)_2$, $-(CH_2)_mSO_2NH_2$, and $-(CH_2)_mSO_2NH$-alkyl, wherein m is 0, 1, 2, or 3;

R^1 and R^2 are independently hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein the aryl, heteroaryl, arylalkyl or heteroarylalkyl is optionally substituted with one, two, or three groups independently selected from the group consisting of alkyl, O-alkyl, S-alkyl, OH, SH, -CN, halogen, 1,3-dioxolanyl, CF_3, NO_2, NH_2, $NHCH_3$, $N(CH_3)_2$, NHCO-alkyl,

$-(CH_2)_mCO_2H$, $-(CH_2)_mCO_2$-alkyl, $-(CH_2)_mSO_3H$, -NH-alkyl, $-N(alkyl)_2$, $-(CH_2)_mPO_3H_2$, $-(CH_2)_mPO_3(alkyl)_2$, $-(CH_2)_mSO_2NH_2$, $-(CH_2)_m$-heteroaryl, $-(CH_2)_mS$-aryl, $-(CH_2)_mS$-heteroaryl, $-(CH_2)_mSO_2$-aryl, $-(CH_2)_mSO_2$-heteroaryl, and $-(CH_2)_mSO_2NH$-alkyl, wherein m is 0, 1, 2, or 3, and wherein each of the R^1 and R^2 groups can be attached through a linker, or through a lower alkyl optionally interrupted by a linker, said linker selected from the group consisting of -NHC-, -CNH, -CO-, S, SO, SO_2, O, and NR^c;

Y is NR^c, O, $-CHR^c$, or S;

n is 0, 2, or 3, provided that when the imidazole is attached at the imidazole nitrogen to $(CR^aR^b)_n$ and Y is O, NR^c or S, then n is not 0; and

R^3 is aryl, heteroarylalkyl, or arylalkyl, wherein the aryl, heteroaryl or arylalkyl is optionally substituted with up to three groups selected from the group consisting of halogen, (C_1-C_6)-alkyl, amino, (C_1-C_6)-alkoxy, hydroxy, trifluoromethyl, mono- or dialkylamino, (C_1-C_6)-thioalkoxy, cyano, nitro, 1,3-dioxolanyl, $NHCO(C_1-C_6)$-alkyl, $(CH_2)_mCO_2H$, $(CH_2)_mCO_2(C_1-C_6)$-alkyl, $(CH_2)_mSO_3H$, $-(CH_2)_mPO_3H_2$, $(CH_2)_mPO_3[(C_1-C_6)\text{-alkyl}]_2$, $(CH_2)_mSO_2NH_2$, and $(CH_2)_mSO_2NH(C_1-C_6)$-alkyl, wherein m is 0, 1, 2, or 3.

2. A compound of formula



VI

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof,

wherein:

R^1 and R^2 are independently hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein the aryl, heteroaryl, arylalkyl or heteroarylalkyl is optionally substituted with one, two, or three groups independently selected from the group consisting of alkyl, O-alkyl, S-alkyl, OH, SH, -CN, halogen, 1,3-dioxolanyl, CF_3, NO_2, NH_2, $NHCH_3$, $N(CH_3)_2$, NHCO-alkyl, $-(CH_2)_mCO_2H$, $-(CH_2)_mCO_2$-alkyl, $-(CH_2)_mSO_3H$, -NH-alkyl, $-N(alkyl)_2$, $-(CH_2)_mPO_3H_2$, $-(CH_2)_mPO_3(alkyl)_2$, $-(CH_2)_mSO_2NH_2$, $-(CH_2)_m$-heteroaryl, $-(CH_2)_mS$-aryl, $-(CH_2)_mS$-heteroaryl, $-(CH_2)_mSO_2$-aryl, $-(CH_2)_mSO_2$-heteroaryl, and $-(CH_2)_mSO_2NH$-alkyl, wherein m is 0, 1, 2, or 3; and wherein each of the R^1 and R^2 groups can be attached through a linker, or through a lower alkyl optionally interrupted by a linker, said linker selected from the group consisting of -NHC-, -CNH, -CO-, S, SO, SO_2, O, and NR^c;

R^c is hydrogen, $(C_1\text{-}C_6)$-alkyl, or aryl;

q is 1 or 2;

R^4 is hydrogen, heteroaryl, or aryl, wherein the aryl or heteroaryl is optionally substituted with up to three groups selected from the group consisting of halogen, $(C_1\text{-}C_6)$-alkyl, amino, $(C_1\text{-}C_6)$-alkoxy, hydroxy, trifluoromethyl, mono- or dialkylamino, $(C_1\text{-}C_6)$-thioalkoxy, cyano, nitro, 1,3-dioxolanyl, $NHCO(C_1\text{-}C_6)$-alkyl, $(CH_2)_mCO_2H$, $(CH_2)_mCO_2(C_1\text{-}C_6)$-alkyl, $(CH_2)_mSO_3H$, $-(CH_2)_mPO_3H_2$, $(CH_2)_mPO_3[(C_1\text{-}C_6)\text{-alkyl}]_2$, $(CH_2)_mSO_2NH_2$, and $(CH_2)_mSO_2NH(C_1\text{-}C_6)$-alkyl, wherein m is 0, 1, 2, or 3; and

R^3 is aryl, heteroarylalkyl, or arylalkyl, wherein the aryl, heteroaryl or arylalkyl is optionally substituted with up to three groups selected from the group consisting of halogen, $(C_1\text{-}C_6)$-alkyl, amino, $(C_1\text{-}C_6)$-alkoxy, hydroxy, trifluoromethyl, mono- or dialkylamino, $(C_1\text{-}C_6)$-thioalkoxy, cyano, nitro, 1,3-dioxolanyl, $NHCO(C_1\text{-}C_6)$-alkyl, $(CH_2)_mCO_2H$, $(CH_2)_mCO_2(C_1\text{-}C_6)$-alkyl, $(CH_2)_mSO_3H$, $-(CH_2)_mPO_3H_2$, $(CH_2)_mPO_3[(C_1\text{-}C_6)\text{-alkyl}]_2$, $(CH_2)_mSO_2NH_2$, and $(CH_2)_mSO_2NH(C_1\text{-}C_6)$-alkyl, wherein m is 0, 1, 2, or 3.

3. A compound of formula



VII

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof,

wherein:

R^1 and R^2 are independently hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein the aryl, heteroaryl, arylalkyl or heteroarylalkyl is optionally substituted with one, two, or three groups independently selected from the group consisting of alkyl, O-alkyl, S-alkyl, OH, SH, -CN, halogen, 1,3-dioxolanyl, CF_3, NO_2, NH_2, $NHCH_3$, $N(CH_3)_2$, NHCO-alkyl, $-(CH_2)_mCO_2H$, $-(CH_2)_mCO_2$-alkyl, $-(CH_2)_mSO_3H$, -NH-alkyl, $-N(alkyl)_2$, $-(CH_2)_mPO_3H_2$, $-(CH_2)_mPO_3(alkyl)_2$, $-(CH_2)_mSO_2NH_2$, $-(CH_2)_m$-heteroaryl, $-(CH_2)_mS$-aryl, $-(CH_2)_mS$-heteroaryl, $-(CH_2)_mSO_2$-aryl, $-(CH_2)_mSO_2$-heteroaryl, and $-(CH_2)_mSO_2NH$-alkyl, wherein m is 0, 1, 2, or 3; and wherein each of the R^1 and R^2 groups can be attached through a linker, or through a lower alkyl optionally interrupted by a linker, said linker selected from the group consisting of -NHC-, -CNH, -CO-, S, SO, SO_2, O, and NR^c;

R^c is hydrogen, $(C_1\text{-}C_6)$-alkyl, or aryl;

q is 1 or 2;

R^4 is hydrogen, heteroaryl, or aryl, wherein the aryl or heteroaryl is optionally substituted with up to three groups selected from the group consisting of halogen, $(C_1\text{-}C_6)$-alkyl, amino, $(C_1\text{-}C_6)$-alkoxy, hydroxy, trifluoromethyl, mono- or dialkylamino, $(C_1\text{-}C_6)$-thioalkoxy, cyano, nitro, 1,3-dioxolanyl, $NHCO(C_1\text{-}C_6)$-alkyl, $(CH_2)_mCO_2H$, $(CH_2)_mCO_2(C_1\text{-}C_6)$-alkyl, $(CH_2)_mSO_3H$, $-(CH_2)_mPO_3H_2$, $(CH_2)_mPO_3\,[(C_1\text{-}C_6)\text{-alkyl}]_2$, $(CH_2)_mSO_2NH_2$, and $(CH_2)_mSO_2NH(C_1\text{-}C_6)$-alkyl, wherein m is 0, 1, 2, or 3; and

R^5 is aryl optionally substituted with up to three groups selected from the group consisting of halogen, $(C_1\text{-}C_6)$-alkyl, amino, $(C_1\text{-}C_6)$-alkoxy, hydroxy, trifluoromethyl, mono- or dialkylamino, $(C_1\text{-}C_6)$-thioalkoxy, cyano, nitro, 1,3-dioxolanyl, $NHCO(C_1\text{-}C_6)$-alkyl, $(CH_2)_mCO_2H$, $(CH_2)_mCO_2(C_1\text{-}C_6)$-alkyl, $(CH_2)_mSO_3H$, $-(CH_2)_mPO_3H_2$, $(CH_2)_mPO_3[(C_1\text{-}C_6)\text{-alkyl}]_2$, $(CH_2)_mSO_2NH_2$, and $(CH_2)_mSO_2NH(C_1\text{-}C_6)$-alkyl, wherein m is 0, 1, 2, or 3.

4. A compound of formula



VIII

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof,

wherein:

R^1 and R^2 are independently hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein the aryl, heteroaryl, arylalkyl or heteroarylalkyl is optionally substituted with one, two, or three groups independently selected from the group consisting of alkyl, O-alkyl, S-alkyl, OH, SH, -CN, halogen, 1,3-dioxolanyl, CF_3, NO_2, NH_2, $NHCH_3$, $N(CH_3)_2$, NHCO-alkyl, $-(CH_2)_mCO_2H$, $-(CH_2)_mCO_2$-alkyl, $-(CH_2)_mSO_3H$, -NH-alkyl, $-N(alkyl)_2$, $-(CH_2)_mPO_3H_2$, $-(CH_2)_mPO_3(alkyl)_2$, $-(CH_2)_mSO_2NH_2$, $-(CH_2)_m$-heteroaryl, $-(CH_2)_mS$-aryl,

$-(CH_2)_mS$-heteroaryl, $-(CH_2)_mSO_2$-aryl, $-(CH_2)_mSO_2$-heteroaryl, and $-(CH_2)_mSO_2NH$-alkyl, wherein m is 0, 1, 2, or 3; and wherein each of the R^1 and R^2 groups can be attached through a linker, or through a lower alkyl optionally interrupted by a linker, said linker selected from the group consisting of -NHC-, -CNH, -CO-, S, SO, SO_2, O, and NR^c;

R^c is hydrogen, (C_1-C_6)-alkyl, or aryl;

q is 1 or 2;

R^4 is hydrogen, heteroaryl, or aryl, wherein the aryl or heteroaryl is optionally substituted with up to three groups selected from the group consisting of halogen, (C_1-C_6)-alkyl, amino, (C_1-C_6)-alkoxy, hydroxy, trifluoromethyl, mono- or dialkylamino, (C_1-C_6)-thioalkoxy, cyano, nitro, 1,3-dioxolanyl, $NHCO(C_1-C_6)$-alkyl, $(CH_2)_mCO_2H$, $(CH_2)_mCO_2(C_1-C_6)$-alkyl, $(CH_2)_mSO_3H$, $-(CH_2)_mPO_3H_2$, $(CH_2)_mPO_3[(C_1-C_6)\text{-alkyl}]_2$, $(CH_2)_mSO_2NH_2$, and $(CH_2)_mSO_2NH(C_1-C_6)$-alkyl, wherein m is 0, 1, 2, or 3; and

R^5 is aryl optionally substituted with up to three groups selected from the group consisting of halogen, (C_1-C_6)-alkyl, amino, (C_1-C_6)-alkoxy, hydroxy, trifluoromethyl, mono- or dialkylamino, (C_1-C_6)-thioalkoxy, cyano, nitro, 1,3-dioxolanyl, $NHCO(C_1-C_6)$-alkyl, $(CH_2)_mCO_2H$, $(CH_2)_mCO_2(C_1-C_6)$-alkyl, $(CH_2)_mSO_3H$, $-(CH_2)_mPO_3H_2$, $(CH_2)_mPO_3[(C_1-C_6)\text{-alkyl}]_2$, $(CH_2)_mSO_2NH_2$, and $(CH_2)_mSO_2NH(C_1-C_6)$-alkyl, wherein m is 0, 1, 2, or 3.

5. A compound according to Claim 1 wherein R^1 is hydrogen.

6. A compound according to Claim 1 wherein R^2 is hydrogen, lower alkyl, arylalkyl, arylaminoalkyl, arylamino, arylcarbonylamino, alkoxyalkyl, or alkoxycarbonylalkyl.

7. A compound according to Claim 1 wherein Y is O.

8. A compound according to Claim 1 wherein n is 2.

9. A compound according to Claim 1 wherein R^a and R^b are hydrogen.

10. A compound according to Claim 1 wherein R^c is hydrogen.

11. A compound according to Claim 1 wherein R^3 is arylalkyl.

12. A compound of formula



IX

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof,

wherein:

R^2 is hydrogen, $(C_1\text{-}C_6)$-alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein the aryl, heteroaryl, arylalkyl, or heteroarylalkyl is optionally substituted with a group independently selected from the group consisting of alkyl, O-alkyl, S-alkyl, OH,

SH, -CN, halogen, 1,3-dioxolanyl, CF_3, NO_2, NH_2, $NHCH_3$, $N(CH_3)_2$, NHCO-alkyl, $-(CH_2)_mCO_2H$, $-(CH_2)_mCO_2$-alkyl, $-(CH_2)_mSO_3H$, -NH-alkyl, $-N(alkyl)_2$, $-(CH_2)_mPO_3H_2$, $-(CH_2)_mPO_3(alkyl)_2$, $-(CH_2)_mSO_2NH_2$, $-(CH_2)_m$-heteroaryl, $-(CH_2)_mS$-aryl, $-(CH_2)_mS$-heteroaryl, $-(CH_2)_mSO_2$-aryl, $-(CH_2)_mSO_2$-heteroaryl, and $-(CH_2)_mSO_2NH$-alkyl, wherein m is 0, 1, 2, or 3, and wherein each of the R^1 and R^2 groups can be attached through a linker, or through a lower alkyl optionally interrupted by a linker, said linker

selected from the group consisting of -NHC-, -CNH, -CO-, S, SO, SO_2, O, and NH;

R^4 is hydrogen or phenyl; and

R^5 is aryl optionally substituted by $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkoxy, or cyano.

13. A compound of formula



X

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof,

wherein:

R^2 is hydrogen, $(C_1\text{-}C_6)$-alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein the aryl, heteroaryl, arylalkyl, or heteroarylalkyl is optionally substituted with a group independently selected from the group consisting of alkyl, O-alkyl, S-alkyl, OH, SH, -CN, halogen, 1,3-dioxolanyl, CF_3, NO_2, NH_2, $NHCH_3$, $N(CH_3)_2$, NHCO-alkyl, $-(CH_2)_mCO_2H$, $-(CH_2)_mCO_2$-alkyl, $-(CH_2)_mSO_3H$, -NH-alkyl, $-N(alkyl)_2$, $-(CH_2)_mPO_3H_2$, $-(CH_2)_mPO_3(alkyl)_2$, $-(CH_2)_mSO_2NH_2$, $-(CH_2)_m$-heteroaryl, $-(CH_2)_mS$-aryl, $-(CH_2)_mS$-heteroaryl, $-(CH_2)_mSO_2$-aryl, $-(CH_2)_mSO_2$-heteroaryl, and $-(CH_2)_mSO_2NH$-alkyl, wherein m is 0, 1, 2, or 3, and wherein each of the R^1 and R^2 groups can be attached through a linker, or through a lower alkyl optionally interrupted by a linker, said linker selected from the group consisting of -NHC-, -CNH, -CO-, S, SO, SO_2, O, and NH;

R^4 is hydrogen or phenyl; and

R^5 is aryl optionally substituted by $(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkoxy, or cyano.

14. A compound of Claim 12 or 13 wherein R^2 is hydrogen, $(C_1\text{-}C_6)$-alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl.

15. A compound of Claim 14 wherein the arylalkyl is substituted with $-(CH_2)_mCO_2H$.

16. A compound of Claim 12 or 13 wherein the linker is selected from the group consisting of –NHCO, $-CO_2$, SO_2, O, and –NH.

17. A compound of Claim 16 wherein R^2 is $(C_1\text{-}C_6)$-alkyl, aryl, or heteroaryl.

18. A compound of Claim 12 or 13 wherein R^4 is hydrogen.

19. A compound according to Claim 1, which is selected from:

4-{5-[2-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl] imidazol-1-ylmethyl}benzonitrile;

4-{5-[2-(5-oxo-1-phenethyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl]imidazol-1-ylmethyl}benzonitrile;

4-(2-{2-[2-(3-benzyl-3H-imidazol-4-yl)ethoxy]-5-oxo-5,6,7, 8-tetrahydronaphthalen-1-yl}ethyl)benzoic acid;

6-[2-(3-benzyl-3H-imidazol-4-yl)ethoxy]-5-phenylaminomethyl-3,4-dihydro-2H-naphthalene-1-one;

5-benzyl-6-[2-(3-benzyl-3H-imidazol-4-yl)ethoxy]-3,4-dihydro-2H-naphthalene-1-one;

6-[2-(3-benzyl-3H-imidazol-4-yl)ethoxy]-5-phenylamino-3, 4-dihydro-2H-naphthalene-1-one;

N-{2-[2-(3-benzyl-3H-imidazol-4-yl)ethoxy]-5-oxo-5,6,7, 8-tetrahydro-naphthalene-1-yl}benzamide;

6-[2-(3-benzyl-3H-imidazol-4-yl)ethoxy]-5-isopropoxymethyl-3,4-dihydro-2H-naphthalene-1-one;

3-{2-[2-(3-benzyl-3H-imidazol-4-yl)ethoxy]-5-oxo-5,6,7, 8-tetrahydro-naphthalene-1-yl}propionic acid methyl ester;

6-[2-(3-benzyl-3H-imidazol-4-yl)-1-phenylethoxy]-3,4-dihydro-2H-naphthalene-1-one;

4-{3-[2-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl]-3H-imidazol-4-yl}methyl)benzonitrile;

6-[2-(5-benzyl-imidazol-1-yl)ethoxy]-5-propyl-3,4-dihydro-2H-naphthalene-1-one;

6-[2-(5-benzyl-imidazol-1-yl)ethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalene-1-one;

4-{3-[2-(5-oxo-1-phenethyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl]-3H-imidazol-4-yl}methyl)benzonitrile;

4-(2-{2-[2-(5-benzyl-imidazol-1-yl)ethoxy]-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl}ethyl)benzoic acid;

6-[2-(5-benzyl-imidazol-1-yl)ethoxy]-5-phenylaminomethyl-3,4-dihydro-2H-naphthalene-1-one;

5-benzyl-6-[2-(5-benzyl-imidazol-1-yl)ethoxy]-3,4-dihydro-2H-naphthalene-1-one;

6-[2-(5-benzyl-imidazol-1-yl)ethoxy]-5-phenylamino-3,4-dihydro-2H-naphthalene-1-one;

N-{2-[2-(5-benzyl-imidazol-1-yl)ethoxy]-5-oxo-5,6,7,8-tetrahydro-naphthalene-1-yl}benzamide;

6-{2-[3-(methoxy-3-methylbenzyl)-3H-imidazol-4-yl]ethoxy}-5-phenethyl-3,4-dihydro-2H-naphthalene-1-one;

6-{2-[3-(4-methoxy-3-methyl-benzyl)-3H-imidazol-4-yl]-ethoxy}-3,4-dihydro-2H-naphthalen-1-one;

6-[2-(3-benzyl-3H-imidazol-4-yl)-ethoxy]-5-propyl-3,4-dihydro-2H-naphthalen-1-one;

6-[2-(3-Benzyl-3H-imidazol-4-yl)-ethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one

6-[2-(5-Benzyl-3H-imidazol-1-yl)-ethoxy]-5-(2-pyridin-2-yl-ethyl)-3,4-dihydro-2H-naphthalene-1-one;

6-{2-[3-(4-Methoxy-3-methylbenzyl)-3H-imidazol-4-yl]ethoxy}-5-(2-pyridin-2-ylethyl)-3,4-dihydro-2H-naphthalene-1-one;

5-Benzenesulfonylmethyl-6-{2-[5-(4-methoxy-3-methylbenzyl)imidazol-1-yl]ethoxy}-3,4-dihydro-2H-naphthalene-1-one;

5-Benzenesulfonylmethyl-6-{2-[3-(4-methoxy-3-methylbenzyl)-3H-imidazol-4-yl]ethoxy}-3,4-dihydro-2H-naphthalene-1-one;

4-({5-[2-({5-Oxo-1-[(2-pyridinylsulfonyl)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl}oxy)ethyl]-1H-imidazol-1-yl}methyl)-benzonitrile; and

4-({5-[2-({1[(Isopropylsulfonyl)methyl]-5-oxo-5,6,7,8-tetrahydro-2-naphthalenyl}oxy)ethyl]-1H-imidazol-1-yl}methyl)benzonitrile.

20. A compound of claim 1, which is 4-({5-[2-({5-Oxo-1-[(2-pyridinylsulfonyl)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl}oxy)ethyl]-1H-imidazol-1-yl}methyl)-benzonitrile or 4-({5-[2-({1[(Isopropylsulfonyl)methyl]-5-oxo-5,6,7,8-tetrahydro-2-naphthalenyl}oxy)ethyl]-1H-imidazol-1-yl}methyl)benzonitrile.

21. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent.

22. A method of treating or preventing restenosis or atherosclerosis, the method comprising administering to a patient having restenosis or atherosclerosis or at risk of having restenosis or atherosclerosis a therapeutically effective amount of a compound of Claim 1.

23. A method of treating cancer, the method comprising administering to a patient having cancer a therapeutically effective amount of a compound of Claim 1.